These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18060072)

  • 1. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.
    Okitsu SL; Silvie O; Westerfeld N; Curcic M; Kammer AR; Mueller MS; Sauerwein RW; Robinson JA; Genton B; Mazier D; Zurbriggen R; Pluschke G
    PLoS One; 2007 Dec; 2(12):e1278. PubMed ID: 18060072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.
    Okitsu SL; Mueller MS; Amacker M; Vogel D; Westerfeld N; Robinson JA; Zurbriggen R; Pluschke G
    Hum Vaccin; 2008; 4(2):106-14. PubMed ID: 18382133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
    Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R
    PLoS One; 2007 Oct; 2(10):e1018. PubMed ID: 17925866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation.
    Okitsu SL; Kienzl U; Moehle K; Silvie O; Peduzzi E; Mueller MS; Sauerwein RW; Matile H; Zurbriggen R; Mazier D; Robinson JA; Pluschke G
    Chem Biol; 2007 May; 14(5):577-87. PubMed ID: 17524988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.
    Mueller MS; Renard A; Boato F; Vogel D; Naegeli M; Zurbriggen R; Robinson JA; Pluschke G
    Infect Immun; 2003 Aug; 71(8):4749-58. PubMed ID: 12874357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.
    Tamborrini M; Mueller MS; Stoffel SA; Westerfeld N; Vogel D; Boato F; Zurbriggen R; Robinson JA; Pluschke G
    Malar J; 2009 Dec; 8():314. PubMed ID: 20042100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.
    Cech PG; Aebi T; Abdallah MS; Mpina M; Machunda EB; Westerfeld N; Stoffel SA; Zurbriggen R; Pluschke G; Tanner M; Daubenberger C; Genton B; Abdulla S
    PLoS One; 2011; 6(7):e22273. PubMed ID: 21799810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
    Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
    Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.
    Gregson AL; Oliveira G; Othoro C; Calvo-Calle JM; Thorton GB; Nardin E; Edelman R
    PLoS One; 2008 Feb; 3(2):e1556. PubMed ID: 18253503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.
    Zenklusen I; Jongo S; Abdulla S; Ramadhani K; Lee Sim BK; Cardamone H; Flannery EL; Nguyen T; Fishbaugher M; Steel RWJ; Betz W; Carmago N; Mikolajczak S; Kappe SHI; Hoffman SL; Sack BK; Daubenberger C
    J Infect Dis; 2018 Apr; 217(10):1569-1578. PubMed ID: 29438525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites.
    Okitsu SL; Boato F; Mueller MS; Li DB; Vogel D; Westerfeld N; Zurbriggen R; Robinson JA; Pluschke G
    Peptides; 2007 Oct; 28(10):2051-60. PubMed ID: 17875342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
    Thompson FM; Porter DW; Okitsu SL; Westerfeld N; Vogel D; Todryk S; Poulton I; Correa S; Hutchings C; Berthoud T; Dunachie S; Andrews L; Williams JL; Sinden R; Gilbert SC; Pluschke G; Zurbriggen R; Hill AV
    PLoS One; 2008 Jan; 3(1):e1493. PubMed ID: 18231580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.
    Kubler-Kielb J; Majadly F; Biesova Z; Mocca CP; Guo C; Nussenzweig R; Nussenzweig V; Mishra S; Wu Y; Miller LH; Keith JM; Liu TY; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 2010 Jan; 107(3):1172-7. PubMed ID: 20080619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
    Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
    Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.